Wen Chen is a Partner at Yonjin Venture and Yonghua Capital, both subsidiary firms of the Shanghai-based Yongjin Group. Wen's professional journey commenced in the pharmaceutical R&D sector, where he worked with several domestic and international companies. His initial position was at TCM1 Science and Technology Development Inc., followed by significant roles at IgCon Therapeutics and Applied Cell Technologies.

Subsequently, Wen held key positions as Senior Vice President at Huya International and Vice President at HD Biosciences. Prior to his current engagement with Yonjin Venture and Yonghua Capital, Wen made notable contributions as Senior Vice President of Business Development at Tiger Pharmaceutical Technology (300347.SZ). Over his decade-long tenure, he played a pivotal role in the company's ascent as a leading clinical CRO in China.

Educationally, Wen earned his Bachelor's degree in Biochemistry from Purdue University and a Master'degree in Medicine from Washington University in St. Louis, USA. He further augmented his academic credentials with an MBA from Durham University in the United Kingdom.